Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

NCT03531905 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2
Cholesterolemia

Interventions

DRUG: Bempedoic acid + Ezetimibe FDC Oral Tablet
DRUG: Ezetimibe 10 mg Oral Tablet
DRUG: Placebo Oral Tablet
DRUG: Placebo oral capsule

Sponsor

Esperion Therapeutics, Inc.